ALECTINIB for Lung adenocarcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 575 adverse event reports in the FDA FAERS database where ALECTINIB was used for Lung adenocarcinoma.
Most Reported Side Effects for ALECTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 702 | 7.7% | 697 | 23 |
| Fatigue | 618 | 6.8% | 12 | 78 |
| Constipation | 525 | 5.7% | 16 | 77 |
| Off label use | 495 | 5.4% | 43 | 43 |
| No adverse event | 488 | 5.3% | 0 | 2 |
| Disease progression | 366 | 4.0% | 64 | 31 |
| Rash | 312 | 3.4% | 5 | 54 |
| Dyspnoea | 296 | 3.2% | 22 | 110 |
| Drug ineffective | 269 | 2.9% | 47 | 25 |
| Myalgia | 268 | 2.9% | 1 | 21 |
| Anaemia | 267 | 2.9% | 9 | 47 |
| Asthenia | 258 | 2.8% | 15 | 38 |
| Weight increased | 237 | 2.6% | 2 | 18 |
| Nausea | 225 | 2.5% | 10 | 59 |
| Diarrhoea | 204 | 2.2% | 13 | 40 |
Other Indications for ALECTINIB
Lung neoplasm malignant (2,932)
Non-small cell lung cancer (1,946)
Product used for unknown indication (1,303)
Non-small cell lung cancer metastatic (627)
Lung cancer metastatic (421)
Bronchial carcinoma (339)
Neoplasm malignant (211)
Metastases to central nervous system (120)
Lung carcinoma cell type unspecified stage 0 (71)
Metastases to bone (71)
Other Drugs Used for Lung adenocarcinoma
PEMETREXED (4,280)
PEMBROLIZUMAB (3,954)
CARBOPLATIN (3,888)
BEVACIZUMAB (1,522)
PACLITAXEL (1,216)
NIVOLUMAB (1,162)
ATEZOLIZUMAB (1,032)
CISPLATIN (1,003)
DOCETAXEL (977)
OSIMERTINIB (936)